SastaSundar Ventures Ltd, a Kolkata-based digital healthcare firm, has unveiled an ambitious plan to invest Rs. 150 crore over the next two years in technology, warehousing, and generics-driven retail to steer the company back to profitability by FY26. This investment, primarily funded by proceeds from its Flipkart Health exit and internal reserves, will support the expansion of its B2C platform, the development of AI-powered healthcare tools, and the rollout of its generic medicines brand JITO. SastaSundar is also focusing on scaling its distribution network and B2B arm, RetailerShakti, aiming for sustainable EBITDA margins by FY30.
Strategic Investment to Power Turnaround
SastaSundar Ventures is intensifying its efforts to transform its business trajectory with a Rs. 150-crore investment blueprint focused on digital infrastructure, warehousing, and retail innovation. Following the conclusion of its partnership with Flipkart Health, the company has relaunched its direct-to-consumer platform under its own brand, targeting profitability in FY26 after reporting a net loss of Rs. 122 crore in FY25.
According to B L Mittal, chairman of SastaSundar Ventures, Rs. 40 crore has already been deployed in FY25, with the balance Rs. 110 crore to be invested over FY26 and FY27. The funds stem largely from a Rs. 145-crore capital pool generated from the Flipkart settlement and internal treasury income.
Focus on Technology, AI, and Generics
A key pillar of SastaSundar’s growth strategy is its planned Rs. 50-crore investment in technology and artificial intelligence. The company intends to build digital consultation tools, diagnostic solutions, and personal health profiling services — innovations aimed at doubling its B2C revenue from Rs. 144 crore in FY25.
Additionally, SastaSundar is expanding its reach in the generics space through JITO, its curated channel for quality-verified generic medicines. An estimated Rs. 25 crore will be allocated to scaling this platform, capitalizing on growing consumer demand for affordable alternatives to branded drugs.
Distribution and B2B Growth
On the distribution front, the company’s Health Buddies network, which plays a crucial role in last-mile delivery and customer engagement, is projected to grow from 250 active partners post-Flipkart exit to around 400 by the end of FY26.
Meanwhile, SastaSundar’s B2B arm, RetailerShakti, which supplies to pharmacies, has demonstrated strong momentum, nearly doubling its revenue to Rs. 941 crore in FY25. The company is targeting EBITDA breakeven for this division in the final quarter of FY26.
Roadmap to Sustainable Profitability
SastaSundar’s broader vision extends to achieving blended EBITDA margins of 4%–5% by FY30, driven by capital-efficient growth and product-led innovation. The company’s strategic realignment, backed by disciplined investment and technology adoption, positions it to leverage India’s rapidly expanding digital healthcare market while addressing the critical need for affordable, quality medication.
Comments